United Kingdom national guideline for the management of prostatitis.

GUIDELINE TITLE
United Kingdom national guideline for the management of prostatitis.
British Association for Sexual Health and HIV

BIBLIOGRAPHIC SOURCE(S)
Clinical Effectiveness Group. United Kingdom national guideline on the management of prostatitis. London (UK): British Association for Sexual Health and HIV (BASHH); 2008. 26 p. [127 references]

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD). 2002 national guideline for the management of prostatitis. London: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD); 2002. Various p. [93 references]

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

April 14, 2009 - Rocephin (ceftriaxone sodium): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of an update to a previous alert that addresses the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. Based on the results from recent in vitro studies, FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients >28 days of age, using the precautionary recommendations noted because the risk of precipitation is low in this population. FDA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.

abrir aquí para acceder al documento NGC AHRQ completo:
United Kingdom national guideline for the management of prostatitis.